<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Acta Ophthalmol</journal-id><journal-id journal-id-type="iso-abbrev">Acta Ophthalmol</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1755-3768</journal-id><journal-id journal-id-type="publisher-id">AOS</journal-id><journal-title-group><journal-title>Acta Ophthalmologica</journal-title></journal-title-group><issn pub-type="ppub">1755-375X</issn><issn pub-type="epub">1755-3768</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27682985</article-id><article-id pub-id-type="pmc">5516226</article-id><article-id pub-id-type="doi">10.1111/aos.13255</article-id><article-id pub-id-type="publisher-id">AOS13255</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Portable electronic vision enhancement systems in comparison with optical magnifiers for near vision activities: an economic evaluation alongside a randomized crossover trial</article-title><alt-title alt-title-type="left-running-head"><sc>acta ophthalmologica</sc> 2016</alt-title></title-group><contrib-group><contrib id="aos13255-cr-0001" contrib-type="author" corresp="yes"><name><surname>Bray</surname><given-names>Nathan</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7646-5435</contrib-id><address><email>n.bray@bangor.ac.uk</email></address><xref ref-type="aff" rid="aos13255-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="aos13255-cr-0002" contrib-type="author"><name><surname>Brand</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="aos13255-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="aos13255-cr-0003" contrib-type="author"><name><surname>Taylor</surname><given-names>John</given-names></name><xref ref-type="aff" rid="aos13255-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="aos13255-cr-0004" contrib-type="author"><name><surname>Hoare</surname><given-names>Zoe</given-names></name><xref ref-type="aff" rid="aos13255-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="aos13255-cr-0005" contrib-type="author"><name><surname>Dickinson</surname><given-names>Christine</given-names></name><xref ref-type="aff" rid="aos13255-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="aos13255-cr-0006" contrib-type="author"><name><surname>Edwards</surname><given-names>Rhiannon T.</given-names></name><xref ref-type="aff" rid="aos13255-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aos13255-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Centre for Health Economics and Medicines Evaluation</named-content>
<institution>Bangor University</institution>
<named-content content-type="city">Bangor</named-content>
<named-content content-type="city">Gwynedd</named-content>
<country country="GB">UK</country>
</aff><aff id="aos13255-aff-0002">
<label><sup>2</sup></label>
<institution>North Wales Organisation for Randomised Trials in Health</institution>
<named-content content-type="city">Bangor</named-content>
<named-content content-type="city">Gwynedd</named-content>
<country country="GB">UK</country>
</aff><aff id="aos13255-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Faculty of Life Sciences</named-content>
<institution>The University of Manchester</institution>
<named-content content-type="city">Manchester</named-content>
<country country="GB">UK</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><italic>Correspondence:</italic><break/>
Nathan Bray<break/>
Centre for Health Economics and Medicines Evaluation<break/>
Bangor University<break/>
Ardudwy, Normal Site<break/>
Bangor<break/>
Gwynedd LL57 2PZ<break/>
UK<break/>
Tel: +44 1248 382814<break/>
Email: <email>n.bray@bangor.ac.uk</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>9</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>8</month><year>2017</year></pub-date><volume>95</volume><issue>5</issue><issue-id pub-id-type="doi">10.1111/aos.2017.95.issue-5</issue-id><fpage>e415</fpage><lpage>e423</lpage><history><date date-type="received"><day>04</day><month>4</month><year>2016</year></date><date date-type="accepted"><day>31</day><month>7</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2017 Acta Ophthalmologica Scandinavica Foundation <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2016 The Authors. <italic>Acta Ophthalmologica</italic> published by John Wiley &#x00026; Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation and European Association for Vision &#x00026; Eye Research.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:AOS-95-e415.pdf"/><abstract id="aos13255-abs-0001"><title>Abstract</title><sec id="aos13255-sec-0001"><title>Purpose</title><p>To determine the incremental cost&#x02010;effectiveness of portable electronic vision enhancement system (p&#x02010;<styled-content style="fixed-case">EVES</styled-content>) devices compared with optical low vision aids (<styled-content style="fixed-case">LVA</styled-content>s), for improving near vision visual function, quality of life and well&#x02010;being of people with a visual impairment.</p></sec><sec id="aos13255-sec-0002"><title>Methods</title><p>An <styled-content style="fixed-case">AB</styled-content>/<styled-content style="fixed-case">BA</styled-content> randomized crossover trial design was used. Eighty&#x02010;two participants completed the study. Participants were current users of optical <styled-content style="fixed-case">LVA</styled-content>s who had not tried a p&#x02010;<styled-content style="fixed-case">EVES</styled-content> device before and had a stable visual impairment. The trial intervention was the addition of a p&#x02010;<styled-content style="fixed-case">EVES</styled-content> device to the participant's existing optical <styled-content style="fixed-case">LVA</styled-content>(s) for 2&#x000a0;months, and the control intervention was optical <styled-content style="fixed-case">LVA</styled-content> use only, for 2&#x000a0;months. Cost&#x02010;effectiveness and cost&#x02010;utility analyses were conducted from a societal perspective.</p></sec><sec id="aos13255-sec-0003"><title>Results</title><p>The mean cost of the p&#x02010;<styled-content style="fixed-case">EVES</styled-content> intervention was &#x000a3;448. Carer costs were &#x000a3;30 (4.46&#x000a0;hr) less for the p&#x02010;<styled-content style="fixed-case">EVES</styled-content> intervention compared with the <styled-content style="fixed-case">LVA</styled-content> only control. The mean difference in total costs was &#x000a3;417. Bootstrapping gave an incremental cost&#x02010;effectiveness ratio (ICER) of &#x000a3;736 (95% <styled-content style="fixed-case">CI</styled-content> &#x000a3;481 to &#x000a3;1525) for a 7% improvement in near vision visual function. Cost per quality&#x02010;adjusted life year (<styled-content style="fixed-case">QALY</styled-content>) ranged from &#x000a3;56&#x000a0;991 (lower 95% <styled-content style="fixed-case">CI</styled-content>&#x000a0;=&#x000a0;&#x000a3;19&#x000a0;801) to &#x000a3;66&#x000a0;490 (lower 95% <styled-content style="fixed-case">CI</styled-content>&#x000a0;=&#x000a0;&#x000a3;23&#x000a0;055). Sensitivity analysis varying the commercial price of the p&#x02010;<styled-content style="fixed-case">EVES</styled-content> device reduced ICERs by up to 75%, with cost per <styled-content style="fixed-case">QALY</styled-content>s falling below &#x000a3;30&#x000a0;000.</p></sec><sec id="aos13255-sec-0004"><title>Conclusion</title><p>Portable electronic vision enhancement system (p&#x02010;<styled-content style="fixed-case">EVES</styled-content>) devices are likely to be a cost&#x02010;effective use of healthcare resources for improving near vision visual function, but this does not translate into cost&#x02010;effective improvements in quality of life, capability or well&#x02010;being.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="aos13255-kwd-0001">economic evaluation</kwd><kwd id="aos13255-kwd-0002">health economics</kwd><kwd id="aos13255-kwd-0003">low vision aid</kwd><kwd id="aos13255-kwd-0004">portable electronic vision enhancement system</kwd><kwd id="aos13255-kwd-0005">visual impairment</kwd></kwd-group><funding-group><award-group><funding-source>National Institute for Health Research (NIHR)</funding-source><award-id>PB&#x02010;PG&#x02010;0211&#x02010;24105</award-id></award-group></funding-group><counts><fig-count count="2"/><table-count count="4"/><page-count count="9"/><word-count count="7785"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>aos13255</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>August 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.1.4 mode:remove_FC converted:19.07.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="aos13255-ntgp-0001"><fn id="aos13255-note-1001"><p>The results reported in this paper were presented at the Association for Research in Vision and Ophthalmology conference in Seattle, USA, May 1&#x02013;5, 2016.</p></fn><fn id="aos13255-note-1002"><p>This publication presents independent research funded by the National Institute for Health Research (NIHR) under its Research for Patient Benefit (RfPB) Programme (Grant Reference Number PB&#x02010;PG&#x02010;0211&#x02010;24105). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The funding organization had no role in the design or conduct of this research. We thank Associated Optical, Bierley, Humanware, Optima Low Vision and Optelec for supplying electronic magnifiers to be used in the study. We also thank John Collins, Paul Fletcher and Max Reinecker for their expertise regarding the p&#x02010;EVES devices; Michael Crossland for his role as independent advisor to the study; and Kate Barugh for vital administrative support. We thank Joan Stelmack for use of the algorithms to Rasch analyse the VFQ responses.</p></fn></fn-group></notes></front><body><sec id="aos13255-sec-0005"><title>Introduction</title><p>One of the major issues faced by people with visual impairment (VI) is the inability to perform simple tasks such as reading and writing. In the United Kingdom (UK), National Health Service (NHS) low vision clinics assess the needs of people with VI and provide low vision aids (LVAs), such as optical magnifiers, as a means to relieve some of the difficulties in performing everyday tasks. Due to the simple nature of these devices, patients often require a variety of aids for different tasks. There is evidence that some optical LVAs are never used due to the limitations of these devices (McIlwaine et&#x000a0;al. <xref rid="aos13255-bib-0018" ref-type="ref">1991</xref>).</p><p>In recent times, electronic alternatives to optical magnifiers have become more readily available as prices of electronic equipment have fallen. Portable electronic vision enhancement systems (p&#x02010;EVES) are becoming a relatively inexpensive way for people with VI to enhance their ability to complete simple tasks without additional assistance (see Fig.&#x000a0;<xref rid="aos13255-fig-0001" ref-type="fig">1</xref> for an example of a p&#x02010;EVES device). The additional benefits of p&#x02010;EVES systems over traditional optical magnifiers include binocular viewing, habitual working distance, variable magnification, adjustable contrast settings and freeze frame facility (Taylor et&#x000a0;al. <xref rid="aos13255-bib-0028" ref-type="ref">2014</xref>). In the Welsh NHS low vision service, p&#x02010;EVES devices are now provided to eligible patients and anecdotal evidence suggests that they are both popular and successful (Charlton et&#x000a0;al. <xref rid="aos13255-bib-0005" ref-type="ref">2011</xref>). However, at present p&#x02010;EVES devices are not routinely provided by NHS low vision services throughout the rest of the UK.</p><fig fig-type="Figure" xml:lang="en" id="aos13255-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Left: The Optelec Compact + which was one of the portable electronic vision enhancement systems (p&#x02010;<styled-content style="fixed-case">EVES</styled-content>) models used in the study, set at minimum magnification. Right: The Eschenbach 5&#x000d7; illuminated fixed&#x02010;focus stand magnifier, which was one of the most common optical low vision aids (<styled-content style="fixed-case">LVA</styled-content>s) used by study participants. There is reflection of room lighting from the lens surface, and image distortion; these would be less noticeable if used with a close eye&#x02010;to&#x02010;magnifier distance, which would also increase field of view.</p></caption><graphic id="nlm-graphic-1" xlink:href="AOS-95-e415-g001"/></fig><p>The hypothesis is that in comparison with optical LVAs, the p&#x02010;EVES devices are less tiring to use and thus can be used for a longer duration and that they are more versatile so can be used for a wider range of tasks. If this is the case, the user will experience greater independence and is likely to rate their health&#x02010;related quality of life (HRQoL) and well&#x02010;being more highly. Previous research has shown only limited evidence that non&#x02010;portable EVES devices are more effective than optical LVAs at improving performance of everyday tasks (Peterson et&#x000a0;al. <xref rid="aos13255-bib-0025" ref-type="ref">2003</xref>; Culham et&#x000a0;al. <xref rid="aos13255-bib-0006" ref-type="ref">2004</xref>), and to date, there has been no published evidence regarding the effectiveness and cost&#x02010;effectiveness of p&#x02010;EVES devices.</p><p>Visual impairment (VI) is known to be one of the leading causes of depression in older people; 13% of people with VI have significant depressive symptoms (Evans et&#x000a0;al. <xref rid="aos13255-bib-0011" ref-type="ref">2007</xref>), 75% of whom are not currently receiving treatment (Nollett et&#x000a0;al. <xref rid="aos13255-bib-0023" ref-type="ref">2016</xref>). Services and adaptations to help people with VI could potentially be an effective and cost&#x02010;effective means of improving the independence, mental health and quality of life of people with untreatable VI.</p><p>Our aim was to firstly determine the incremental cost&#x02010;effectiveness of use of a p&#x02010;EVES device plus optical LVA compared with optical LVA use alone (using &#x02018;near vision&#x02019; visual function as the measure of effect). Secondly, we aimed to estimate the cost per quality&#x02010;adjusted life year (QALY) gained from use of a p&#x02010;EVES device plus optical LVA compared with optical LVA use alone.</p></sec><sec id="aos13255-sec-0006"><title>Patients and Methods</title><sec id="aos13255-sec-0007"><title>Design</title><p>The p&#x02010;EVES study was a single&#x02010;centre two&#x02010;arm randomized crossover study designed to determine the acceptability, effectiveness and cost&#x02010;effectiveness of p&#x02010;EVES devices as compared to optical LVAs for &#x02018;near vision&#x02019; tasks in adults with moderate to severe visual impairment. In this paper, we report on cost&#x02010;effectiveness; full effectiveness results will be reported in a separate paper which is currently under review (Taylor J, Bambrick R, Brand A, Bray N, Dutton M, Harper RA, Hoare Z, Ryan B, Edwards RT, Waterman H, Dickinson CM; unpublished data), and a qualitative paper reporting acceptability is currently being prepared. The p&#x02010;EVES study was conducted at Manchester Royal Eye Hospital, UK. A published study protocol describes the study design and methodology in detail (Taylor et&#x000a0;al. <xref rid="aos13255-bib-0028" ref-type="ref">2014</xref>). The p&#x02010;EVES study was registered with clinical trials.gov (Identifier: NCT01701700), received favourable National Research Ethics Service (NRES) ethical approval and conformed to the tenets of the Declaration of Helsinki. Written informed consent was obtained from all participants.</p></sec><sec id="aos13255-sec-0008"><title>Study population</title><p>The trial was carried out between 2013 and 2015 in Manchester, UK. Participants were recruited through optometrist led low vision clinics at the Manchester Royal Eye Hospital. Patients were considered eligible to participate if they were aged 18 or over, had a visual impairment secondary to a stable ocular pathology, had binocular distance visual acuity of 0.7 or worse and/or log contrast sensitivity of 1.20 or worse and were currently in possession of at least one near vision optical LVA. A total of 780 patients from low vision clinics at Manchester Royal Eye Hospital were assessed, 680 were excluded and 100 randomized. Of the 680 excluded, 533 did not meet the inclusion criteria, 117 declined, 27 could not be contacted, and in three cases, the recruitment forms completed by referring clinicians were illegible.</p></sec><sec id="aos13255-sec-0009"><title>Intervention</title><p>An AB/BA crossover trial design was used. Participants were randomly allocated to one of two possible study arms: Group 1 or Group 2. Group 1 received the two interventions A and B in the order AB, while Group 2 received the interventions in the order BA. Intervention A was a 2&#x02010;month period using optical LVAs and a p&#x02010;EVES device. Intervention B was a 2&#x02010;month control period using optical LVAs only. During intervention A, optical LVAs were retained: they could be used for tasks for which the p&#x02010;EVES was not suitable, or instead of the p&#x02010;EVES if preferred. Additional information is provided in the previously published protocol (Taylor et&#x000a0;al. <xref rid="aos13255-bib-0028" ref-type="ref">2014</xref>).</p><p>Participants selected one of four possible p&#x02010;EVES devices depending on their needs: the Optelec Compact 4HD (&#x000a3;545), the Optelec Compact+ (&#x000a3;249), the Schweizer eMag 43 (&#x000a3;399) and the Eschenbach Mobilux Digital (&#x000a3;399). As per current NHS practice, participants were not given extended formal training on how to use the p&#x02010;EVES devices beyond basic operational demonstration.</p></sec><sec id="aos13255-sec-0010"><title>Intervention adherence</title><p>Adherence was considered in two ways: firstly, did the participants engage with the purpose of the study and try to use the p&#x02010;EVES to carry out a range of tasks, and, secondly, did participants find the p&#x02010;EVES useful enough to persist with it. Regarding the first point, participants in each arm of the study were phoned after 1&#x000a0;week to ask about any difficulties in using the devices, and to arrange re&#x02010;instruction if required. For each participant, the Manchester Low Vision Questionnaire (MLVQ) was used to record the frequency of use of aids; the type/number of tasks completed using each aid; the longest duration of use of each aid; and the type/number of tasks that could not be completed using each aid (or which required additional assistance).</p></sec><sec id="aos13255-sec-0011"><title>Measurement of effectiveness</title><p>Two primary measures of effectiveness were used: near vision visual function, as measured using the NV&#x02010;VFQ&#x02010;15 (Stelmack &#x00026; Massof <xref rid="aos13255-bib-0027" ref-type="ref">2007</xref>), for the cost&#x02010;effectiveness analysis; and vision&#x02010;related quality of life, as measured using the VisQoL (Misajon et&#x000a0;al. <xref rid="aos13255-bib-0019" ref-type="ref">2005</xref>), for cost&#x02010;utility analysis. The EQ&#x02010;5D&#x02010;5L (Herdman et&#x000a0;al. <xref rid="aos13255-bib-0012" ref-type="ref">2011</xref>), ICECAP&#x02010;A (Al&#x02010;Janabi et&#x000a0;al. <xref rid="aos13255-bib-0001" ref-type="ref">2012</xref>) and WHO&#x02010;5 (Bonsignore et&#x000a0;al. <xref rid="aos13255-bib-0002" ref-type="ref">2001</xref>) were used as part of sensitivity analyses to examine the effect of different measures on results.</p></sec><sec id="aos13255-sec-0012"><title>Outcome measures</title><p>The NV&#x02010;VFQ&#x02010;15 is a 15&#x02010;item &#x02018;near vision&#x02019; visual function outcome measure which was developed for this study from the &#x02018;near vision&#x02019; items on the NV&#x02010;VFQ&#x02010;48 (Stelmack &#x00026; Massof <xref rid="aos13255-bib-0027" ref-type="ref">2007</xref>). A validated algorithm for scoring vision function questionnaires was used to score the NV&#x02010;VFQ&#x02010;15 (Massof <xref rid="aos13255-bib-0017" ref-type="ref">2007</xref>). This scoring approximates a Rasch analysis. Using this scoring system, the lowest possible &#x02018;near vision&#x02019; visual function score on the NV&#x02010;VFQ&#x02010;15 is &#x02212;3.36 logits, and the highest possible score is 5.07 logits, therefore resulting in a total score scale out of 8.43 logits.</p><p>The VisQoL is specifically designed to measure vision&#x02010;related quality of life (Misajon et&#x000a0;al. <xref rid="aos13255-bib-0019" ref-type="ref">2005</xref>) and is one of the first outcome measures to allow utility values and QALYs to be calculated for the purpose of economic evaluation in vision&#x02010;related interventions (Peacock et&#x000a0;al. <xref rid="aos13255-bib-0024" ref-type="ref">2008</xref>). It is scored from 0 (state of death) to 1 (perfect health).</p><p>The EQ&#x02010;5D is a generic, validated HRQoL measure (EuroQoL Group <xref rid="aos13255-bib-0010" ref-type="ref">1990</xref>). We used the five&#x02010;level (5L) version of the EQ&#x02010;5D as this is considered to be more sensitive than the original three&#x02010;level (3L) version (Janssen et&#x000a0;al. <xref rid="aos13255-bib-0014" ref-type="ref">2013</xref>). At the time of analysis, a validated UK value set was not available to score the EQ&#x02010;5D&#x02010;5L, and therefore, a crosswalk value set was used to assign weights for domain levels based on the 3L scoring system (van Hout et&#x000a0;al. <xref rid="aos13255-bib-0013" ref-type="ref">2012</xref>). The EQ&#x02010;5D&#x02010;5L was analysed to produce an index score between 0 (state of death) and 1 (perfect health).</p><p>The ICECAP&#x02010;A is a validated capability measure focussing on well&#x02010;being beyond health and is scored from 0 (no capability) to 1 (full capability) (Al&#x02010;Janabi et&#x000a0;al. <xref rid="aos13255-bib-0001" ref-type="ref">2012</xref>). The WHO&#x02010;5 is a validated emotional well&#x02010;being index, which is highly sensitive for screening depressive symptoms (Lowe et&#x000a0;al. <xref rid="aos13255-bib-0016" ref-type="ref">2004</xref>). A total score out of 100 is calculated from the raw score.</p></sec><sec id="aos13255-sec-0013"><title>Measurement of costs</title><sec id="aos13255-sec-0014"><title>Costing the intervention</title><p>Costs for the p&#x02010;EVES devices ranged from &#x000a3;249 to &#x000a3;545 per device. Additional staff time in low vision clinics for demonstration of the devices was collected and costed. Salary costs were estimated using published NHS banding data for 2014/2015 (Royal College of Nursing <xref rid="aos13255-bib-0026" ref-type="ref">2014</xref>). With an applied overhead rate of 60.7% (Curtis <xref rid="aos13255-bib-0008" ref-type="ref">2011</xref>), per hour p&#x02010;EVES device demonstration costs equated to &#x000a3;24.52.</p></sec><sec id="aos13255-sec-0015"><title>Costing carer time</title><p>See Table&#x000a0;<xref rid="aos13255-tbl-0001" ref-type="table-wrap">1</xref> for a breakdown of carer tasks, time codes and costs. Costs were calculated for change in carer time elicited by the availability of the p&#x02010;EVES aid as compared to access to optical LVAs only. Due to the crossover design, this was measured as change from baseline (Visit 1) to Visit 2 for Group 1, and change from Visit 2 to Visit 3 for Group 2, as Group 2 essentially had a staggered baseline due to the &#x02018;BA&#x02019; order of interventions. The results are reported as carer time freed up through use of p&#x02010;EVES. Carer time was costed at an hourly rate of &#x000a3;6.80 (Curtis <xref rid="aos13255-bib-0009" ref-type="ref">2014</xref>).</p><table-wrap id="aos13255-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Costing carer time: MLVQ near vision tasks and assumptions applied to unit costs</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">MLVQ near vision task</th><th align="left" valign="top" rowspan="1" colspan="1">Estimated time (minutes)</th><th align="left" valign="top" rowspan="1" colspan="1">Estimated carer cost (&#x000a3;)<xref ref-type="fn" rid="aos13255-note-0004">a</xref>
</th><th align="left" valign="top" rowspan="1" colspan="1">Estimated frequency if not stated</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Reading letters/cards/other correspondence</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">&#x000a3;1.70</td><td align="left" rowspan="1" colspan="1">Daily</td></tr><tr><td align="left" rowspan="1" colspan="1">Reading instructions (packets, tins, bottles, medicines, etc.)</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">&#x000a3;1.70</td><td align="left" rowspan="1" colspan="1">Daily</td></tr><tr><td align="left" rowspan="1" colspan="1">Reading &#x02018;ordinary&#x02019; print books/newspapers/magazines</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">&#x000a3;3.40</td><td align="left" rowspan="1" colspan="1">Daily</td></tr><tr><td align="left" rowspan="1" colspan="1">Reading telephone directory to check numbers</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">&#x000a3;0.57</td><td align="left" rowspan="1" colspan="1">Weekly</td></tr><tr><td align="left" rowspan="1" colspan="1">Reading markings on dial (cooker, radio/hi&#x02010;fi, washer, etc.)</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">&#x000a3;0.57</td><td align="left" rowspan="1" colspan="1">Daily</td></tr><tr><td align="left" rowspan="1" colspan="1">Reading shop prices/labels</td><td align="left" rowspan="1" colspan="1">60</td><td align="left" rowspan="1" colspan="1">&#x000a3;6.80</td><td align="left" rowspan="1" colspan="1">Twice weekly</td></tr><tr><td align="left" rowspan="1" colspan="1">Read the time on your watch</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">&#x000a3;0.57</td><td align="left" rowspan="1" colspan="1">Daily</td></tr><tr><td align="left" rowspan="1" colspan="1">Reading large print books/newspapers</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">&#x000a3;3.40</td><td align="left" rowspan="1" colspan="1">Daily</td></tr><tr><td align="left" rowspan="1" colspan="1">Identifying money</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">&#x000a3;0.57</td><td align="left" rowspan="1" colspan="1">Daily</td></tr><tr><td align="left" rowspan="1" colspan="1">Writing own letters, cards, etc.</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">&#x000a3;3.40</td><td align="left" rowspan="1" colspan="1">Weekly</td></tr><tr><td align="left" rowspan="1" colspan="1">Signing your own name</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">&#x000a3;0.57</td><td align="left" rowspan="1" colspan="1">Twice weekly</td></tr><tr><td align="left" rowspan="1" colspan="1">Reading own writing</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">&#x000a3;1.70</td><td align="left" rowspan="1" colspan="1">Weekly</td></tr><tr><td align="left" rowspan="1" colspan="1">Filling in cheques, forms, etc.</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">&#x000a3;3.40</td><td align="left" rowspan="1" colspan="1">Weekly</td></tr><tr><td align="left" rowspan="1" colspan="1">Special hobby (e.g. stamps, models, painting, music)</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">&#x000a3;3.40</td><td align="left" rowspan="1" colspan="1">Weekly</td></tr><tr><td align="left" rowspan="1" colspan="1">DIY/repair/fixing task</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">&#x000a3;3.40</td><td align="left" rowspan="1" colspan="1">Weekly</td></tr><tr><td align="left" rowspan="1" colspan="1">Sewing/knitting/needlework/mending</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">&#x000a3;3.40</td><td align="left" rowspan="1" colspan="1">Weekly</td></tr><tr><td align="left" rowspan="1" colspan="1">Watching TV</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">&#x000a3;1.70</td><td align="left" rowspan="1" colspan="1">Daily</td></tr><tr><td align="left" rowspan="1" colspan="1">Reading street signs/bus numbers/directions etc.</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">&#x000a3;0.57</td><td align="left" rowspan="1" colspan="1">Twice weekly</td></tr><tr><td align="left" rowspan="1" colspan="1">Watching an event/trip/theatre</td><td align="left" rowspan="1" colspan="1">180<xref ref-type="fn" rid="aos13255-note-0005">b</xref>
</td><td align="left" rowspan="1" colspan="1">&#x000a3;20.40</td><td align="left" rowspan="1" colspan="1">Monthly</td></tr><tr><td align="left" rowspan="1" colspan="1">Mobile phone</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">&#x000a3;1.70</td><td align="left" rowspan="1" colspan="1">Daily</td></tr><tr><td align="left" rowspan="1" colspan="1">Looking at photographs</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">&#x000a3;1.70</td><td align="left" rowspan="1" colspan="1">Daily</td></tr><tr><td align="left" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr></tbody></table><table-wrap-foot><fn id="aos13255-note-0004"><label>a</label><p>Based on gross hourly salary of &#x000a3;6.80 for public and independent sector care worker (Curtis <xref rid="aos13255-bib-0009" ref-type="ref">2014</xref>).</p></fn><fn id="aos13255-note-0005"><label>b</label><p>Includes travel and activity time for carer, as carer would need to be present throughout.</p></fn><fn id="aos13255-note-0006"><p>MLVQ&#x000a0;=&#x000a0;Manchester Low Vision Questionnaire, DIY&#x000a0;=&#x000a0;do it yourself.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>Need for task assistance was measured using the MLVQ, which asks respondents to estimate how often they require assistance from another person on 21 different tasks ranging from reading small print to writing letters. Participants were also asked to estimate daily/weekly frequency and length of time taken for the MLVQ tasks, but participants reported issues in making these estimates. In order to maintain uniformity in the analysis, we consulted with a person with over 40&#x000a0;years&#x02019; experience of living with a VI to aid in assigning time codes and estimating daily/weekly frequencies for each task on the MLVQ.</p></sec></sec><sec id="aos13255-sec-0016"><title>Analysis of effects and costs</title><p>Twelve participants with no follow&#x02010;up data and six participants with only 2&#x02010;month follow&#x02010;up data were excluded from the analyses. Therefore, a total of 82 of 100 randomized participants were included in the economic analyses. A total of 38 participants were randomized to Group 1 and 44 to Group 2.</p><p>CROS t&#x02010;tests were used to account for participant, period and treatment factors. The results indicated that there was not a statistically significant effect of moving from intervention A to intervention B (or vice versa) on any of the economic evaluation measures, and therefore, the data for the two interventions could be grouped by intervention (A or B) across the two study groups, allowing us to expand the sample size to include participants as their own comparators.</p><p>Carer time costs were collated for both groups and compared between the intervention A and intervention B time&#x02010;points. Mean differences in costs between the two interventions were calculated using nonparametric bootstrapping, and run on 5000 iterations, to produce 95% confidence intervals around these differences (Briggs et&#x000a0;al. <xref rid="aos13255-bib-0004" ref-type="ref">1997</xref>). Discounting was not undertaken as the length of interventions did not exceed 12&#x000a0;months.</p></sec><sec id="aos13255-sec-0017"><title>Primary cost&#x02010;effectiveness analysis</title><p>All economic analyses were conducted from a societal perspective to take account of the financial burden of carer time. All costs are in &#x000a3; sterling for 2014. The primary cost&#x02010;effectiveness analysis compared change in &#x02018;near vision&#x02019; visual function, as measured using the NV&#x02010;VFQ&#x02010;15, with carer and intervention costs for the two interventions. Due to the crossover design, effectiveness of the p&#x02010;EVES devices was measured as change from baseline (Visit 1) to Visit 2 for Group 1, and change from Visit 2 to Visit 3 for Group 2. Effectiveness of the optical LVA intervention was measured as change from Visit 1 to Visit 3 for Group 1, and change from Visit 1 to Visit 2 for Group 2 to account for the different order of interventions in the two study groups.</p><p>An incremental cost&#x02010;effectiveness ratio (ICER) was estimated using the NV&#x02010;VFQ&#x02010;15 as the measure of effect. Bootstrapping, based on 5000 iterations, was used to generate 95% confidence intervals around the ICER estimates. An ICER plane was generated to show the distribution of costs and effects, and a cost&#x02010;effectiveness acceptability curve (CEAC) was generated to show the probability of cost&#x02010;effectiveness at a specified threshold of &#x000a3;1000 per point improvement on the NV&#x02010;VFQ&#x02010;15.</p></sec><sec id="aos13255-sec-0018"><title>Primary cost&#x02010;utility analysis</title><p>The QALY is a well&#x02010;established outcome measure in health economics which is used to aggregate the quantity and quality of life experienced in a given health state. In the UK, the National Institute for Health and Care Excellence (NICE) specifically endorses the QALY as a primary outcome measure in economic evaluations (NICE <xref rid="aos13255-bib-0022" ref-type="ref">2013</xref>). Previous research has indicated that generic measures such as the EQ&#x02010;5D are not sensitive to quality of life changes related to vision and visual function (Tosh et&#x000a0;al. <xref rid="aos13255-bib-0029" ref-type="ref">2012</xref>). The VisQoL was therefore used as the primary outcome measure to generate a cost per QALY, ICER plane and CEAC for comparison with the NICE ceiling of &#x000a3;20&#x000a0;000 to &#x000a3;30&#x000a0;000 per QALY in the UK (NICE <xref rid="aos13255-bib-0022" ref-type="ref">2013</xref>).</p><p>Area under the curve (AUC) calculations were used to estimate the overall utility experienced during the different intervention periods, and therefore ICER calculations were based on difference in utility experienced during each 2&#x02010;month intervention period.</p><p>In order to calculate AUC, a baseline score is required; however, due to the crossover design, participants in Group 1 received the p&#x02010;EVES intervention before the optical LVA only control. This meant that calculating AUC for the optical LVA intervention was not possible for Group 1 without introducing bias due to prior experience with a p&#x02010;EVES device. Therefore, optical LVA AUC data was only used from Group 2. This resulted in a sample size of <italic>N</italic>&#x000a0;=&#x000a0;82 in the p&#x02010;EVES plus optical LVA intervention arm and <italic>N</italic>&#x000a0;=&#x000a0;44 in the optical LVA only arm.</p></sec><sec id="aos13255-sec-0019"><title>Sensitivity analysis: outcome measures</title><p>Using the bootstrapping methods detailed earlier, probabilistic sensitivity analysis was conducted to generate ICER planes illustrating variation in cost&#x02010;effectiveness from varying basic assumptions about effectiveness and costs.</p><p>Deterministic sensitivity analysis was conducted by altering the effectiveness results and costs of the intervention; secondary cost&#x02010;effectiveness, cost&#x02010;utility and cost&#x02010;capability analyses were carried out to examine the effect of different outcome measures on the economic evaluation results. In the cost&#x02010;effectiveness sensitivity analysis, the WHO&#x02010;5 was used as an alternative measure of effectiveness due to the high incidence of depression in this population (Evans et&#x000a0;al. <xref rid="aos13255-bib-0011" ref-type="ref">2007</xref>). In the cost&#x02010;utility sensitivity analysis, the EQ&#x02010;5D&#x02010;5L was used as an alternative measure of utility. Additionally, the ICECAP&#x02010;A was used to calculate an estimated cost per year of full capability (YFC); the YFC approach is an alternative to the QALY framework which focuses on a broader measurement of well&#x02010;being beyond health and physical functioning (Mitchell et&#x000a0;al. <xref rid="aos13255-bib-0020" ref-type="ref">2015</xref>).</p></sec><sec id="aos13255-sec-0020"><title>Sensitivity analysis: intervention costs</title><p>Three adjusted intervention cost sensitivity analyses were undertaken. In the first sensitivity analysis, the highest cost device (&#x000a3;545) was applied to all participants alongside a standardized hour of training (&#x000a3;24.52); in the second, the lowest cost device was applied to all participants (&#x000a3;249) with no training costs; and in the third, a real&#x02010;world Welsh NHS low vision service p&#x02010;EVES cost (&#x000a3;150) was applied to all participants (at the time of this trial the Welsh service used the Compact+, not the &#x000a3;150 low&#x02010;cost device).</p></sec></sec><sec id="aos13255-sec-0021"><title>Results</title><sec id="aos13255-sec-0022"><title>Demographics</title><p>Demographic characteristics of the sample are presented in Table&#x000a0;<xref rid="aos13255-tbl-0002" ref-type="table-wrap">2</xref>.</p><table-wrap id="aos13255-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Demographic and visual characteristics of participants recruited to the study</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Group 1 (<italic>N</italic>&#x000a0;=&#x000a0;49)</th><th align="left" valign="top" rowspan="1" colspan="1">Group 2 (<italic>N</italic>&#x000a0;=&#x000a0;51)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years) mean (SD)</td><td align="left" rowspan="1" colspan="1">69.79 (19.97)</td><td align="left" rowspan="1" colspan="1">72.94 (16.63)</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender Male <italic>n</italic> (%)</td><td align="left" rowspan="1" colspan="1">20 (40.8)</td><td align="left" rowspan="1" colspan="1">18 (35.3)</td></tr><tr><td align="left" colspan="3" rowspan="1">Ethnicity <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">White British</td><td align="left" rowspan="1" colspan="1">45 (91.8)</td><td align="left" rowspan="1" colspan="1">48 (94.1)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1">4 (8.2)</td><td align="left" rowspan="1" colspan="1">3 (5.9)</td></tr><tr><td align="left" colspan="3" rowspan="1">Registration (CVI) status <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">SSI</td><td align="left" rowspan="1" colspan="1">22 (44.9)</td><td align="left" rowspan="1" colspan="1">21 (41.2)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">SI</td><td align="left" rowspan="1" colspan="1">18 (36.7)</td><td align="left" rowspan="1" colspan="1">25 (49.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Not registered</td><td align="left" rowspan="1" colspan="1">9 (18.4)</td><td align="left" rowspan="1" colspan="1">5 (9.8)</td></tr><tr><td align="left" colspan="3" rowspan="1">Residential status <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Alone</td><td align="left" rowspan="1" colspan="1">19 (38.8)</td><td align="left" rowspan="1" colspan="1">24 (47.1)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">With spouse/partner</td><td align="left" rowspan="1" colspan="1">11 (22.4)</td><td align="left" rowspan="1" colspan="1">10 (19.6)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">With family/friends</td><td align="left" rowspan="1" colspan="1">19 (38.8)</td><td align="left" rowspan="1" colspan="1">17 (33.3)</td></tr><tr><td align="left" colspan="3" rowspan="1">Employment status <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Employed</td><td align="left" rowspan="1" colspan="1">4 (8.2)</td><td align="left" rowspan="1" colspan="1">3 (5.9)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Unemployed</td><td align="left" rowspan="1" colspan="1">6 (12.2)</td><td align="left" rowspan="1" colspan="1">7 (13.7)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Retired</td><td align="left" rowspan="1" colspan="1">38 (77.6)</td><td align="left" rowspan="1" colspan="1">41 (80.4)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">FTE</td><td align="left" rowspan="1" colspan="1">1 (2.0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Binocular distance VA (logMAR) mean (SD)</td><td align="left" rowspan="1" colspan="1">0.95 (0.30)</td><td align="left" rowspan="1" colspan="1">0.96 (0.25)</td></tr><tr><td align="left" rowspan="1" colspan="1">Near VA (M units) at 25&#x000a0;cm mean (SD)</td><td align="left" rowspan="1" colspan="1">2.66 (1.67)</td><td align="left" rowspan="1" colspan="1">2.53 (1.32)</td></tr><tr><td align="left" rowspan="1" colspan="1">Central visual field status (CCVFT grade) mean (SD)</td><td align="left" rowspan="1" colspan="1">2.45 (1.42)</td><td align="left" rowspan="1" colspan="1">3.10 (1.54)</td></tr><tr><td align="left" rowspan="1" colspan="1">(Log) Contrast sensitivity (Pelli Robson) mean (SD)</td><td align="left" rowspan="1" colspan="1">0.78 (0.37)</td><td align="left" rowspan="1" colspan="1">0.75 (0.31)</td></tr></tbody></table><table-wrap-foot><fn id="aos13255-note-0007"><p>CCVFT&#x000a0;=&#x000a0;California Central Visual Field Test, CVI&#x000a0;=&#x000a0;Certificate of visual impairment, FTE&#x000a0;=&#x000a0;full&#x02010;time education, SD&#x000a0;=&#x000a0;standard deviation, SI&#x000a0;=&#x000a0;sight impaired, SSI&#x000a0;=&#x000a0;severely sight impaired, VA&#x000a0;=&#x000a0;visual acuity.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="aos13255-sec-0023"><title>Effectiveness</title><p>The mean difference in effect between the p&#x02010;EVES plus optical LVA intervention and optical LVA only intervention equated to a visual ability improvement of 0.567 [95% confidence interval (CI) 0.279 to 0.847] on the NV&#x02010;VFQ&#x02010;15; QALY gains of 0.006 (95% CI &#x02212;0.007 to 0.019) and 0.007 (95% CI &#x02212;0.007 to 0.021) on the VisQoL and EQ&#x02010;5D&#x02010;5L, respectively; well&#x02010;being improvement of 0.292 (&#x02212;5.073 to 5.561) on the WHO&#x02010;5; and YFC gains of 0.007 (95% CI &#x02212;0.004 to 0.016) on the ICECAP&#x02010;A. The CROS t&#x02010;tests revealed a significant treatment effect for the NV&#x02010;VFQ&#x02010;15 [p&#x000a0;&#x0003c;&#x000a0;0.001, ES&#x000a0;=&#x000a0;0.57 (CI 0.33, 0.81)] and VisQoL [p&#x000a0;=&#x000a0;0.04, ES&#x000a0;=&#x000a0;0.01 (CI &#x02212;0.02, 0.05)], but not the WHO&#x02010;5 [p&#x000a0;=&#x000a0;0.884, ES&#x000a0;=&#x000a0;0.32 (CI &#x02212;4.08, 4.72)], EQ&#x02010;5D&#x02010;5L [p&#x000a0;=&#x000a0;0.09, ES&#x000a0;=&#x000a0;0.03 (CI &#x02212;0.01, 0.07)] or ICECAP&#x02010;A [p&#x000a0;=&#x000a0;0.523, ES&#x000a0;=&#x000a0;0.01 (CI &#x02212;0.02, 0.03)].</p><p>The statistical findings therefore indicate that the intervention including p&#x02010;EVES was effective at improving &#x02018;near vision&#x02019; visual function and providing additional QALYs (measured using a vision&#x02010;specific measure) as compared to optical LVAs.</p></sec><sec id="aos13255-sec-0024"><title>Costs</title><sec id="aos13255-sec-0025"><title>Device costs</title><p>Of the 82 participants included in the economic analyses, 28 received a p&#x02010;EVES device costing &#x000a3;545, 50 received a p&#x02010;EVES device costing &#x000a3;399 and four received a p&#x02010;EVES device costing &#x000a3;249. The average cost of a p&#x02010;EVES device was &#x000a3;441.54 (SD &#x000a3;81.53). The analysis was focussed on the incremental costs and benefits of p&#x02010;EVES; therefore, it was not necessary to cost pre&#x02010;existing optical LVAs which participants already had available.</p></sec><sec id="aos13255-sec-0026"><title>Optometrist time costs</title><p>Additional staff time required to demonstrate how to use the p&#x02010;EVES devices ranged from five to 30&#x000a0;min, with an average of 15&#x000a0;min (SD 6). On average, this equated to an additional staff time cost of &#x000a3;5.98 (SD &#x000a3;2.40) per participant. Combined with the p&#x02010;EVES device costs, the average cost of the p&#x02010;EVES plus optical LVA intervention was &#x000a3;447.52 (SD &#x000a3;82.29).</p></sec><sec id="aos13255-sec-0027"><title>Carer time costs</title><p>During the 2&#x02010;month p&#x02010;EVES plus optical LVA intervention period (intervention A), average carer time amounted to 29.28&#x000a0;hr, an opportunity cost of &#x000a3;199.07 (SD &#x000a3;155.44) to the carer(s). During the 2&#x02010;month optical LVA only control period (intervention B), average carer time amounted to 33.74&#x000a0;hr, an opportunity cost of &#x000a3;229.40 (SD &#x000a3;150.89) to the carer(s). The mean difference in carer costs was therefore &#x02212;&#x000a3;30.33 (4.46&#x000a0;hr) with a bootstrapped 95% CI of &#x02212;&#x000a3;76.10 to &#x000a3;15.99, equating to a reduced monthly carer cost of &#x000a3;15.17 per participant.</p></sec><sec id="aos13255-sec-0028"><title>Total costs</title><p>Factoring in the intervention device costs, staff time and carer time costs, a mean difference of &#x000a3;417.19 was found between interventions A and B (total costs of &#x000a3;646.59 and &#x000a3;229.40, respectively), with a bootstrapped 95% CI of &#x000a3;366.04 and &#x000a3;465.89. For the cost&#x02010;utility analysis, the mean difference in total costs was slightly lower at &#x000a3;398.95 (CI &#x000a3;336.69 to &#x000a3;460.15) due to higher mean total costs for the optical LVA subsample (<italic>N</italic>&#x000a0;=&#x000a0;42; &#x000a3;247.64).</p></sec></sec><sec id="aos13255-sec-0029"><title>Primary cost&#x02010;effectiveness analysis</title><p>In total, 164 sets of data were included in the cost&#x02010;effectiveness analyses; 82 participants in both intervention arms, as the crossover design allowed participants to act as their own comparators. See Table&#x000a0;<xref rid="aos13255-tbl-0003" ref-type="table-wrap">3</xref> for a breakdown of effectiveness and ICER results. The mean difference in total costs between the p&#x02010;EVES plus optical LVA intervention arm and the optical LVA only arm (&#x000a3;417.19, CI &#x000a3;366.04 to &#x000a3;465.89) was divided by the mean effect (0.567 NV&#x02010;VFQ&#x02010;15 points), producing an estimated ICER of &#x000a3;735.77 (CI &#x000a3;481.03 to &#x000a3;1525.18) per unit change in &#x02018;near vision&#x02019; visual function.</p><table-wrap id="aos13255-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Economic analysis: Incremental costs (&#x000a3;) and outcomes of p&#x02010;EVES device plus optical LVA as compared to optical LVA alone</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1"/><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">
<bold>Trial outcomes</bold>
</th><th align="left" colspan="2" valign="top" rowspan="1">
<bold>Effectiveness</bold>
</th><th align="left" colspan="2" valign="top" rowspan="1">
<bold>Incremental effectiveness</bold>
</th><th align="left" colspan="2" valign="top" rowspan="1">
<bold>ICER</bold>
</th><th align="left" colspan="3" valign="top" rowspan="1">
<bold>Probability of cost&#x02010;effectiveness</bold>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">
<bold>Baseline mean (SD)</bold>
</th><th align="left" valign="top" rowspan="1" colspan="1">
<bold>p&#x02010;EVES mean (SD)</bold>
</th><th align="left" valign="top" rowspan="1" colspan="1">
<bold>LVA mean (SD)</bold>
</th><th align="left" valign="top" rowspan="1" colspan="1">
<bold>p&#x02010;EVES mean effect (SD)</bold>
</th><th align="left" valign="top" rowspan="1" colspan="1">
<bold>LVA mean effect (SD)</bold>
</th><th align="left" valign="top" rowspan="1" colspan="1">
<bold>Effect mean difference</bold>
</th><th align="left" valign="top" rowspan="1" colspan="1">
<bold>95% CI for mean difference</bold>
</th><th align="left" valign="top" rowspan="1" colspan="1">
<bold>ICER point estimate</bold>
</th><th align="left" valign="top" rowspan="1" colspan="1">
<bold>95% CI for ICER</bold>
</th><th align="left" valign="top" rowspan="1" colspan="1">
<bold>Probability at threshold</bold>
</th><th align="left" valign="top" rowspan="1" colspan="1">
<bold>ICER plane NW %</bold>
</th><th align="left" valign="top" rowspan="1" colspan="1">
<bold>ICER plane NE %</bold>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>NV&#x02010;VFQ&#x02010;15</bold>
</td><td align="left" rowspan="1" colspan="1">1.371 (1.28)</td><td align="left" rowspan="1" colspan="1">2.015 (1.323)</td><td align="left" rowspan="1" colspan="1">1.448 (1.284)</td><td align="left" rowspan="1" colspan="1">0.645<xref ref-type="fn" rid="aos13255-note-0052">b</xref> (1.103)</td><td align="left" rowspan="1" colspan="1">0.078 (0.714)</td><td align="left" rowspan="1" colspan="1">0.567</td><td align="left" rowspan="1" colspan="1">0.279 &#x02013; 0.847</td><td align="left" rowspan="1" colspan="1">&#x000a3;735.77<xref ref-type="fn" rid="aos13255-note-0053">c</xref>
<sup>,</sup>
<xref ref-type="fn" rid="aos13255-note-0056">f</xref>
</td><td align="left" rowspan="1" colspan="1">&#x000a3;481.03 &#x02013; &#x000a3;1525.18</td><td align="left" rowspan="1" colspan="1">0.840<xref ref-type="fn" rid="aos13255-note-0059">i</xref>
</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">5000 (100)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>VisQoL</bold>
<xref ref-type="fn" rid="aos13255-note-0051">a</xref>
</td><td align="left" rowspan="1" colspan="1">0.555 (0.218)</td><td align="left" rowspan="1" colspan="1">0.582 (0.230)</td><td align="left" rowspan="1" colspan="1">0.553 (0.228)</td><td align="left" rowspan="1" colspan="1">0.095<xref ref-type="fn" rid="aos13255-note-0052">b</xref> (0.036)</td><td align="left" rowspan="1" colspan="1">0.089 (0.035)</td><td align="left" rowspan="1" colspan="1">0.006</td><td align="left" rowspan="1" colspan="1">&#x02212;0.007 &#x02013; 0.019</td><td align="left" rowspan="1" colspan="1">&#x000a3;66,490.00<xref ref-type="fn" rid="aos13255-note-0054">d</xref>
<sup>,</sup>
<xref ref-type="fn" rid="aos13255-note-0057">g</xref>
</td><td align="left" rowspan="1" colspan="1">&#x000a3;23,054.5<xref ref-type="fn" rid="aos13255-note-0058">h</xref>
</td><td align="left" rowspan="1" colspan="1">0.14<xref ref-type="fn" rid="aos13255-note-0060">j</xref>
</td><td align="left" rowspan="1" colspan="1">949 (18.98)</td><td align="left" rowspan="1" colspan="1">4051 (81.02)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>EQ&#x02010;5D&#x02013;5L</bold>
<xref ref-type="fn" rid="aos13255-note-0051">a</xref>
</td><td align="left" rowspan="1" colspan="1">0.629 (0.232)</td><td align="left" rowspan="1" colspan="1">0.643 (0.217)</td><td align="left" rowspan="1" colspan="1">0.611 (0.245)</td><td align="left" rowspan="1" colspan="1">0.105 (0.036)</td><td align="left" rowspan="1" colspan="1">0.098 (0.040)</td><td align="left" rowspan="1" colspan="1">0.007</td><td align="left" rowspan="1" colspan="1">&#x02212;0.007 &#x02013; 0.021</td><td align="left" rowspan="1" colspan="1">&#x000a3;56,991.43<xref ref-type="fn" rid="aos13255-note-0054">d</xref>
<sup>,</sup>
<xref ref-type="fn" rid="aos13255-note-0057">g</xref>
</td><td align="left" rowspan="1" colspan="1">&#x000a3;19,801.2<xref ref-type="fn" rid="aos13255-note-0058">h</xref>
</td><td align="left" rowspan="1" colspan="1">0.214<xref ref-type="fn" rid="aos13255-note-0060">j</xref>
</td><td align="left" rowspan="1" colspan="1">803 (16.06)</td><td align="left" rowspan="1" colspan="1">4197 (83.94)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>ICECAP&#x02010;A</bold>
<xref ref-type="fn" rid="aos13255-note-0051">a</xref>
</td><td align="left" rowspan="1" colspan="1">0.729 (0.183)</td><td align="left" rowspan="1" colspan="1">0.755 (0.153)</td><td align="left" rowspan="1" colspan="1">0.746 (0.166)</td><td align="left" rowspan="1" colspan="1">0.125 (0.025)</td><td align="left" rowspan="1" colspan="1">0.118 (0.029)</td><td align="left" rowspan="1" colspan="1">0.007</td><td align="left" rowspan="1" colspan="1">&#x02212;0.004 &#x02013; 0.016</td><td align="left" rowspan="1" colspan="1">&#x000a3;56,991.43<xref ref-type="fn" rid="aos13255-note-0055">e</xref>
<sup>,</sup>
<xref ref-type="fn" rid="aos13255-note-0057">g</xref>
</td><td align="left" rowspan="1" colspan="1">&#x000a3;26,447.6<xref ref-type="fn" rid="aos13255-note-0058">h</xref>
</td><td align="left" rowspan="1" colspan="1">0.094<xref ref-type="fn" rid="aos13255-note-0060">j</xref>
</td><td align="left" rowspan="1" colspan="1">589 (11.78)</td><td align="left" rowspan="1" colspan="1">4411 (88.22)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>WHO&#x02010;5</bold>
</td><td align="left" rowspan="1" colspan="1">54.683 (24.262)</td><td align="left" rowspan="1" colspan="1">55.268 (21.883)</td><td align="left" rowspan="1" colspan="1">54.976 (23.075)</td><td align="left" rowspan="1" colspan="1">0.585 (19.097)</td><td align="left" rowspan="1" colspan="1">0.293 (14.791)</td><td align="left" rowspan="1" colspan="1">0.292</td><td align="left" rowspan="1" colspan="1">&#x02212;5.073 &#x02013; 5.561</td><td align="left" rowspan="1" colspan="1">&#x000a3;1,428.70<xref ref-type="fn" rid="aos13255-note-0053">c</xref>
<sup>,</sup>
<xref ref-type="fn" rid="aos13255-note-0056">f</xref>
</td><td align="left" rowspan="1" colspan="1">&#x000a3;89.27<xref ref-type="fn" rid="aos13255-note-0058">h</xref>
</td><td align="left" rowspan="1" colspan="1">0.438<xref ref-type="fn" rid="aos13255-note-0059">i</xref>
</td><td align="left" rowspan="1" colspan="1">2329 (46.58)</td><td align="left" rowspan="1" colspan="1">2671 (53.42)</td></tr></tbody></table><table-wrap-foot><fn id="aos13255-note-0051"><label>a</label><p>mean effect and ICERs based on 2month area under the curve outcomes</p></fn><fn id="aos13255-note-0052"><label>b</label><p>significant treatment effect p&#x000a0;&#x0003c;&#x000a0;0.05</p></fn><fn id="aos13255-note-0053"><label>c</label><p>cost per point improvement</p></fn><fn id="aos13255-note-0054"><label>d</label><p>cost per QALY</p></fn><fn id="aos13255-note-0055"><label>e</label><p>cost per YFC</p></fn><fn id="aos13255-note-0056"><label>f</label><p>calculated using mean cost difference of &#x000a3;417.19 (full sample)</p></fn><fn id="aos13255-note-0057"><label>g</label><p>calculated using mean cost difference of &#x000a3;398.95 (reduced LVA control sample due to AUC calculation)</p></fn><fn id="aos13255-note-0058"><label>h</label><p>one&#x02010;tailed bootstrapped 5% confidence limit, upper limit could not be calculated</p></fn><fn id="aos13255-note-0059"><label>i</label><p>at &#x000a3;1000 threshold</p></fn><fn id="aos13255-note-0060"><label>j</label><p>at &#x000a3;30,000 threshold</p></fn><fn id="aos13255-note-0061"><p>Abbreviations: AUC&#x000a0;=&#x000a0;area under the curve, CI&#x000a0;=&#x000a0;confidence interval, ICER&#x000a0;=&#x000a0;incremental cost&#x02010;effectiveness ratio, LVA&#x000a0;=&#x000a0;low vision aid, NE&#x000a0;=&#x000a0;North East, NW&#x000a0;=&#x000a0;North West, p&#x02010;EVES&#x000a0;=&#x000a0;portable electronic vision enhancement systems, QALY&#x000a0;=&#x000a0;quality&#x02010;adjusted life year, SD&#x000a0;=&#x000a0;standard deviation, YFC&#x000a0;=&#x000a0;year of full capability.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>Figure&#x000a0;<xref rid="aos13255-fig-0002" ref-type="fig">2</xref>A shows the ICER plane with 5000 points (100%) in the north&#x02010;east quadrant, where the intervention is more costly but more effective. Figure&#x000a0;<xref rid="aos13255-fig-0002" ref-type="fig">2</xref>B presents the corresponding CEAC, which shows the probability of cost&#x02010;effectiveness at a range of thresholds. At a cost of &#x000a3;481.03, the intervention has a 2.5% probability of cost&#x02010;effectiveness; at &#x000a3;1525.18, there is a 97.5% probability of cost&#x02010;effectiveness. The ICER estimate falls between the confidence limits with a cost&#x02010;effectiveness probability of 48% at a cost of &#x000a3;735.77 per unit change. At a threshold of &#x000a3;1000 per point improvement, the NV&#x02010;VFQ&#x02010;15 results demonstrate an 84.4% probability of cost&#x02010;effectiveness.</p><fig fig-type="Figure" xml:lang="en" id="aos13255-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Cost&#x02010;effectiveness planes (A, C) and cost&#x02010;effectiveness acceptability curves (B, D) generated from cost data and <styled-content style="fixed-case">NV</styled-content>&#x02010;<styled-content style="fixed-case">VFQ</styled-content>&#x02010;15 (A, B) and VisQoL (C, D) effectiveness data. ICER&#x000a0;=&#x000a0;Incremental cost&#x02010;effectiveness ratio.</p></caption><graphic id="nlm-graphic-3" xlink:href="AOS-95-e415-g002"/></fig></sec><sec id="aos13255-sec-0030"><title>Primary cost&#x02010;utility analysis</title><p>A total of 82 participants were included in the p&#x02010;EVES plus optical LVA arm and 44 in the optical LVA only control arm (due to issues with AUC caused by the crossover design). See Table&#x000a0;<xref rid="aos13255-tbl-0003" ref-type="table-wrap">3</xref> for a breakdown of effectiveness and ICER results. Effectiveness was expressed as the difference in mean QALYs experienced between the two interventions over a 2&#x02010;month follow&#x02010;up period, which equated to 0.006&#x000a0;years or 2.19&#x000a0;days using the VisQoL as the primary measure of utility. Mean difference in total costs (&#x000a3;398.95, CI &#x000a3;336.69 to &#x000a3;460.15) was divided by the mean difference in effect between the two interventions (0.006, CI &#x02212;0.009 to 0.019), yielding an estimated cost per QALY of &#x000a3;66&#x000a0;490: over double the upper NICE cost threshold of &#x000a3;30&#x000a0;000 per QALY. Using the VisQoL, 19% of the bootstrapped estimates fell in the north&#x02010;west quadrant, where the intervention is more costly and less effective (see Fig.&#x000a0;<xref rid="aos13255-fig-0002" ref-type="fig">2</xref>C). Therefore, because the CEAC did not exceed 81% maximum probability of cost&#x02010;effectiveness, upper confidence limits could not be calculated. A one&#x02010;sided 95% lower confidence limit was calculated at &#x000a3;23 055. Figure&#x000a0;<xref rid="aos13255-fig-0002" ref-type="fig">2</xref>D presents the corresponding CEAC for the VisQoL. At a threshold of &#x000a3;30&#x000a0;000 per QALY, there is a 14% probability of cost&#x02010;effectiveness using the VisQoL as the measure of effect.</p></sec><sec id="aos13255-sec-0031"><title>Sensitivity analysis: secondary cost&#x02010;effectiveness analysis</title><p>A secondary cost&#x02010;effectiveness analysis was conducted using well&#x02010;being (measured using the WHO&#x02010;5) as the measure of effect. See Table&#x000a0;<xref rid="aos13255-tbl-0003" ref-type="table-wrap">3</xref> for effectiveness and ICER results. Mean effect on the WHO&#x02010;5 was calculated at 0.292 (95% CI &#x02212;5.073 to 5.561), producing an ICER of &#x000a3;1428.70 (one&#x02010;tailed lower 95% CI 89.27) per unit change in well&#x02010;being. In total, 2329 (46.6%) of the bootstrapped estimates fell in the north&#x02010;west quadrant, where the intervention is more costly and less effective. At a threshold of &#x000a3;1000 per point improvement, the WHO&#x02010;5 demonstrates a 47.8% probability of cost&#x02010;effectiveness, although it should be noted that this is for a one&#x02010;point improvement on a well&#x02010;being scale scored from 0 to 100.</p></sec><sec id="aos13255-sec-0032"><title>Sensitivity analysis: secondary cost&#x02010;utility and cost&#x02010;capability analysis</title><p>A secondary cost&#x02010;utility analysis was conducted using the EQ&#x02010;5D&#x02010;5L as the measure of utility, and cost&#x02010;capability analysis using the ICECAP&#x02010;A as the measure of capability. See Table&#x000a0;<xref rid="aos13255-tbl-0003" ref-type="table-wrap">3</xref> for effectiveness and ICER results. Effectiveness was expressed as the difference in mean QALYs (EQ&#x02010;5D&#x02010;5L) and YFCs (ICECAP&#x02010;A) experienced between the interventions over a 2&#x02010;month follow&#x02010;up period, which equated to 0.007&#x000a0;years or 2.56&#x000a0;days on both the EQ&#x02010;5D&#x02010;5L and ICECAP&#x02010;A, producing a cost per QALY/YFC of &#x000a3;56 991. One&#x02010;sided 95% lower confidence limits were calculated at &#x000a3;19 801 for the EQ&#x02010;5D&#x02010;5L and &#x000a3;26 448 for ICECAP&#x02010;A. At a threshold of &#x000a3;30&#x000a0;000 per QALY/YFC gain, probability of effectiveness was 21.4% using the EQ&#x02010;5D&#x02010;5L and 9.4% using the ICECAP&#x02010;A.</p></sec><sec id="aos13255-sec-0033"><title>Sensitivity analysis: adjusted intervention costs</title><p>Table&#x000a0;<xref rid="aos13255-tbl-0004" ref-type="table-wrap">4</xref> shows the sensitivity analysis results for all adjusted intervention costs. The higher cost sensitivity analysis (&#x000a3;569.52 per p&#x02010;EVES intervention) increased the mean difference in total costs from &#x000a3;417.19 to &#x000a3;554.19 (&#x000a3;398.95 to &#x000a3;535.95 in cost&#x02010;utility analysis), increasing ICERs by between 33% and 34%. In the lower cost sensitivity analysis (&#x000a3;249 per p&#x02010;EVES intervention), the mean difference in total costs decreased from &#x000a3;417.19 to &#x000a3;233.67 (&#x000a3;398.95 to &#x000a3;215.43 in cost&#x02010;utility analysis), decreasing ICERs by between 46% and 48%. In the &#x02018;real&#x02010;world&#x02019; sensitivity analysis (&#x000a3;150 per p&#x02010;EVES intervention), the mean difference in total costs decreased from &#x000a3;417.19 to &#x000a3;119.67 (&#x000a3;398.95 to &#x000a3;101.43 in cost&#x02010;utility analysis), decreasing ICERs by between 71% and 75%.</p><table-wrap id="aos13255-tbl-0004" xml:lang="en" orientation="portrait" position="float"><label>Table 4</label><caption><p>Sensitivity analysis: adjusted intervention costs results</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Base case ICER</th><th align="left" valign="top" rowspan="1" colspan="1">Lower intervention cost ICER<xref ref-type="fn" rid="aos13255-note-0019">a</xref>
</th><th align="left" valign="top" rowspan="1" colspan="1">Higher intervention cost ICER<xref ref-type="fn" rid="aos13255-note-0020">b</xref>
</th><th align="left" valign="top" rowspan="1" colspan="1">Welsh NHS intervention cost ICER<xref ref-type="fn" rid="aos13255-note-0021">c</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">NV&#x02010;VFQ&#x02010;15</td><td align="left" rowspan="1" colspan="1">&#x000a3;735.77</td><td align="left" rowspan="1" colspan="1">&#x000a3;379.95</td><td align="left" rowspan="1" colspan="1">&#x000a3;977.41</td><td align="left" rowspan="1" colspan="1">&#x000a3;211.06</td></tr><tr><td align="left" rowspan="1" colspan="1">VisQoL</td><td align="left" rowspan="1" colspan="1">&#x000a3;56&#x000a0;991.43</td><td align="left" rowspan="1" colspan="1">&#x000a3;35&#x000a0;905.34</td><td align="left" rowspan="1" colspan="1">&#x000a3;89&#x000a0;325.34</td><td align="left" rowspan="1" colspan="1">&#x000a3;16&#x000a0;904.79</td></tr><tr><td align="left" rowspan="1" colspan="1">EQ&#x02010;5D</td><td align="left" rowspan="1" colspan="1">&#x000a3;66&#x000a0;490.00</td><td align="left" rowspan="1" colspan="1">&#x000a3;30&#x000a0;776.01</td><td align="left" rowspan="1" colspan="1">&#x000a3;76&#x000a0;564.58</td><td align="left" rowspan="1" colspan="1">&#x000a3;14&#x000a0;489.82</td></tr><tr><td align="left" rowspan="1" colspan="1">ICECAP</td><td align="left" rowspan="1" colspan="1">&#x000a3;56&#x000a0;991.43</td><td align="left" rowspan="1" colspan="1">&#x000a3;30&#x000a0;776.01</td><td align="left" rowspan="1" colspan="1">&#x000a3;76&#x000a0;564.58</td><td align="left" rowspan="1" colspan="1">&#x000a3;14&#x000a0;489.82</td></tr><tr><td align="left" rowspan="1" colspan="1">WHO</td><td align="left" rowspan="1" colspan="1">&#x000a3;1428.70</td><td align="left" rowspan="1" colspan="1">&#x000a3;737.78</td><td align="left" rowspan="1" colspan="1">&#x000a3;1897.92</td><td align="left" rowspan="1" colspan="1">409.82</td></tr></tbody></table><table-wrap-foot><fn id="aos13255-note-0019"><label>a</label><p>All device costs reduced to &#x000a3;249, no optometrist time costs.</p></fn><fn id="aos13255-note-0020"><label>b</label><p>All device costs increased to &#x000a3;545, 1&#x000a0;hr optometrist time (&#x000a3;24.52) for all participants.</p></fn><fn id="aos13255-note-0021"><label>c</label><p>All device costs reduced to &#x000a3;150, no optometrist time costs.</p></fn><fn id="aos13255-note-0022"><p>ICER&#x000a0;=&#x000a0;incremental cost&#x02010;effectiveness ratio.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>The sensitivity analyses demonstrate that with lower device costs, p&#x02010;EVES interventions could potentially be cost&#x02010;effective according to the NICE cost per QALY threshold of &#x000a3;20&#x000a0;000 to &#x000a3;30&#x000a0;000; in the &#x02018;real&#x02010;world&#x02019; sensitivity analysis, cost per QALY estimates fell to between &#x000a3;14 490 and &#x000a3;16 905 (EQ&#x02010;5D&#x02010;5L and VisQoL, respectively). It should be noted that the &#x02018;real&#x02010;world&#x02019; p&#x02010;EVES cost of &#x000a3;150 is for a different device to the ones used in this study, and therefore, the equivalence of outcomes can only be assumed.</p></sec></sec><sec id="aos13255-sec-0034"><title>Discussion</title><sec id="aos13255-sec-0035"><title>Summary</title><p>The mean incremental cost, including carer costs, of the p&#x02010;EVES intervention was &#x000a3;417.19. Bootstrapping gave an ICER of &#x000a3;735.83 per unit change in &#x02018;near vision&#x02019; visual function, as measured by the NV&#x02010;VFQ&#x02010;15. Considering that this scale is scored from &#x02212;3.36 to 5.07, the ICER point estimate relates to a 6.7% improvement in &#x02018;near vision&#x02019; visual function. At a threshold of &#x000a3;1000 per point improvement, the p&#x02010;EVES intervention had an 84.4% probability of cost&#x02010;effectiveness using the NV&#x02010;VFQ&#x02010;15 as the measure of effect. Cost per point improvement on the WHO&#x02010;5 was almost 50% over the &#x000a3;1000 threshold, which is particularly high when considering that the scale ranges from 0 to 100.</p><p>QALY and YFC results did not show the p&#x02010;EVES intervention to be cost&#x02010;effective in comparison with optical LVAs; however, sensitivity analyses demonstrated that lower cost p&#x02010;EVES devices could yield better cost&#x02010;effectiveness outcomes. Overall, the results indicate that p&#x02010;EVES devices are a cost&#x02010;effective means of improving &#x02018;near vision&#x02019; visual function for people with a VI, but this does not translate to&#x000a0;equivalent improvements in self&#x02010;reported quality of life, capability or well&#x02010;being.</p><p>Current p&#x02010;EVES devices supplied by the NHS in UK cost approximately &#x000a3;150, on top of the cost of any other optical LVAs the patient may need. This is an important consideration, as the results indicate that p&#x02010;EVES devices could supplement optical LVAs, not replace them. At up to five times the cost of an optical LVA, p&#x02010;EVES devices are an additional cost to NHS low vision services. Even if p&#x02010;EVES were to replace all currently supplied optical LVAs, additional funding would be needed to account for the extra cost of p&#x02010;EVES compared with optical LVAs. The need for additional NHS funding to enable provision of p&#x02010;EVES devices is therefore apparent.</p></sec><sec id="aos13255-sec-0036"><title>Strength and limitations</title><p>Participants were only given 2&#x000a0;months with a p&#x02010;EVES device. It would perhaps have been beneficial to extend the time&#x02010;points to allow more prolonged use of the p&#x02010;EVES devices. It was difficult to collect exact data regarding carer time and activities using the MLVQ as participants had difficulty accurately recalling the frequency and duration of assistance. In order to counter this, we consulted with a person with VI to develop a set of assumptions regarding activity duration and frequency. Although this is not the most robust approach to analysing need for assistance, it allowed us to utilize a uniform approach to costing the data. Due to a lack of certainty in economic evaluations, it is common place for health economists to apply assumptions where robust information or data is not available (Mogyorosy &#x00026; Smith <xref rid="aos13255-bib-0021" ref-type="ref">2005</xref>). We used probabilistic sensitivity analysis, in the form of bootstrapping, to illustrate the variation in cost&#x02010;effectiveness as a result of varying basic assumptions about effectiveness and costs. This accounts for some of the uncertainty in the data as a result of the assumptions made in the analysis.</p><p>The analysis benefited from the incorporation of both a generic and disease&#x02010;specific measure of HRQoL to allow comparisons between measures. Another strength was the inclusion of carer time costs. Loss of productivity and the opportunity costs of informal care are often neglected in economic evaluations, but from a societal perspective these are important considerations.</p></sec><sec id="aos13255-sec-0037"><title>Comparison with other literature</title><p>To our knowledge, this paper presents the first robust cost&#x02010;effectiveness and cost&#x02010;utility analyses of p&#x02010;EVES devices. Although economic evidence is lacking in this field of research, a number of previous studies have compared different types of LVAs, including electronic devices. To date, limited evidence has shown that non&#x02010;portable EVES devices are more effective than optical LVAs at improving &#x02018;near vision&#x02019; tasks such as reading performance. Culham et&#x000a0;al. (<xref rid="aos13255-bib-0006" ref-type="ref">2004</xref>, <xref rid="aos13255-bib-0007" ref-type="ref">2009</xref>) found that some EVES provide better performance of &#x02018;near vision&#x02019; tasks, but likewise optical LVAs were more effective for other tasks. Peterson et&#x000a0;al. (<xref rid="aos13255-bib-0025" ref-type="ref">2003</xref>) found that in general, EVES enabled faster reading speeds, but optical LVAs facilitated faster performance of item location tasks. There is no published evidence about the effectiveness of the most technologically advanced p&#x02010;EVES devices available today, such as those used in this trial.</p></sec><sec id="aos13255-sec-0038"><title>Implications for future research</title><p>Only the NV&#x02010;VFQ&#x02010;15 and VisQoL measures demonstrated a significant treatment effect for the p&#x02010;EVES intervention. The results from the NV&#x02010;VFQ&#x02010;15 suggest that the p&#x02010;EVES intervention could potentially be a cost&#x02010;effective means of improving &#x02018;near vision&#x02019; visual function. However, the results from the preference&#x02010;based utility and capability measures (VisQoL, EQ&#x02010;5D&#x02010;5L and ICECAP&#x02010;A) show that the p&#x02010;EVES intervention could not be proven to be a cost&#x02010;effective approach to improving health status or well&#x02010;being, therefore indicating that improvement to &#x02018;near vision&#x02019; visual function does not drastically affect overall health status, or that standard measures of health and well&#x02010;being are not sufficiently sensitive to measure change in this population.</p><p>Previous literature shows that the EQ&#x02010;5D measures can be insensitive to utility change caused by vision and visual function (Bozzani et&#x000a0;al. <xref rid="aos13255-bib-0003" ref-type="ref">2012</xref>; Longworth et&#x000a0;al. <xref rid="aos13255-bib-0015" ref-type="ref">2014</xref>). In order to examine the appropriateness of vision&#x02010;related and generic measures of utility in this setting, the VisQoL and EQ&#x02010;5D&#x02010;5L were compared in the cost&#x02010;utility analyses.</p><p>The VisQoL was designed to be sensitive to vision&#x02010;related quality of life and is an appropriate means of rapidly estimating utility for the purpose of economic evaluation (Peacock et&#x000a0;al. <xref rid="aos13255-bib-0024" ref-type="ref">2008</xref>). It is therefore interesting that both the VisQoL and EQ&#x02010;5D&#x02010;5L exhibited relatively similar results in terms of incremental utility gains between the intervention arms (VisQoL&#x000a0;=&#x000a0;0.006; EQ&#x02010;5D&#x02010;5L&#x000a0;=&#x000a0;0.007). The EQ&#x02010;5D&#x02010;5L showed greater overall utility estimates&#x000a0;and a lower cost per QALY estimate.</p><p>If we consider the VisQoL to be more sensitive in this population, these results would suggest that the EQ&#x02010;5D&#x02010;5L was in fact overestimating utility in this population, but both are insensitive in picking up utility gains from ability to perform normal tasks. This is an important consideration for future research within this field, as accurate utility measurement is paramount in the calculation of QALYs. Furthermore, only the VisQoL showed a significant difference between the intervention arms. Considering these points, the VisQoL appears to be the most appropriate measure of utility in this setting.</p><p>Using the NV&#x02010;VFQ&#x02010;15, a 0.567 or 6.7% improvement in visual function was found after the p&#x02010;EVES intervention. Equivalently sized changes to utility and capability were not found using any of the measures. It is first important to reiterate that each time&#x02010;point in the study was only 2&#x000a0;months long, and therefore, there may have been insufficient time for the p&#x02010;EVES intervention to facilitate change to broader aspects of health and well&#x02010;being. Furthermore, the NV&#x02010;VFQ&#x02010;15 only measures change in terms of &#x02018;near vision&#x02019; visual function. Quality of life, well&#x02010;being and capability are affected by a large array of factors, and therefore, we would not expect to see equivalent increases to utility as visual function.</p></sec></sec></body><back><ref-list content-type="cited-references" id="aos13255-bibl-0001"><title>References</title><ref id="aos13255-bib-0001"><mixed-citation publication-type="journal" id="aos13255-cit-0001">
<string-name>
<surname>Al&#x02010;Janabi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Flynn</surname>
<given-names>TN</given-names>
</string-name> &#x00026; <string-name>
<surname>Coast</surname>
<given-names>J</given-names>
</string-name> (<year>2012</year>): <article-title>Development of a self&#x02010;report measure of capability wellbeing for adults: The ICECAP&#x02010;A</article-title>. <source>Qual Life Res</source>
<volume>21</volume>: <fpage>167</fpage>&#x02013;<lpage>176</lpage>.<pub-id pub-id-type="pmid">21598064</pub-id></mixed-citation></ref><ref id="aos13255-bib-0002"><mixed-citation publication-type="journal" id="aos13255-cit-0002">
<string-name>
<surname>Bonsignore</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Barkow</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Jessen</surname>
<given-names>F</given-names>
</string-name> &#x00026; <string-name>
<surname>Heun</surname>
<given-names>R</given-names>
</string-name> (<year>2001</year>): <article-title>Validity of the five&#x02010;item WHO Well&#x02010;being Index (WHO&#x02010;5) in an elderly population</article-title>. <source>Eur Arch Psychiatry Clin Neurosci</source>
<volume>251</volume>(<issue>suppl</issue>): <fpage>27</fpage>&#x02013;<lpage>31</lpage>.</mixed-citation></ref><ref id="aos13255-bib-0003"><mixed-citation publication-type="journal" id="aos13255-cit-0003">
<string-name>
<surname>Bozzani</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Alavi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Jofre&#x02010;Bonet</surname>
<given-names>M</given-names>
</string-name> &#x00026; <string-name>
<surname>Kuper</surname>
<given-names>H</given-names>
</string-name> (<year>2012</year>): <article-title>A comparison of the sensitivity of EQ&#x02010;5D, SF&#x02010;6D and TTO utility values to changes in vision and perceived visual function in patients with primary open&#x02010;angle glaucoma</article-title>. <source>BMC Ophthalmol</source>
<volume>12</volume>: <fpage>43</fpage>.<pub-id pub-id-type="pmid">22909264</pub-id></mixed-citation></ref><ref id="aos13255-bib-0004"><mixed-citation publication-type="journal" id="aos13255-cit-0004">
<string-name>
<surname>Briggs</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wonderling</surname>
<given-names>D</given-names>
</string-name> &#x00026; <string-name>
<surname>Mooney</surname>
<given-names>C</given-names>
</string-name> (<year>1997</year>): <article-title>Pulling cost&#x02010;effectiveness analysis up by its bootstraps: a non&#x02010;parametric approach to confidence interval estimation</article-title>. <source>Health Econ</source>
<volume>6</volume>: <fpage>327</fpage>&#x02013;<lpage>340</lpage>.<pub-id pub-id-type="pmid">9285227</pub-id></mixed-citation></ref><ref id="aos13255-bib-0005"><mixed-citation publication-type="journal" id="aos13255-cit-0005">
<string-name>
<surname>Charlton</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jenkins</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Rhodes</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Martin&#x02010;Smith</surname>
<given-names>T</given-names>
</string-name> &#x00026; <string-name>
<surname>Ryan</surname>
<given-names>B</given-names>
</string-name> (<year>2011</year>): <article-title>The Welsh low vision service&#x02010;a summary</article-title>. <source>Optom Pract</source>
<volume>12</volume>: <fpage>29</fpage>&#x02013;<lpage>38</lpage>.</mixed-citation></ref><ref id="aos13255-bib-0006"><mixed-citation publication-type="journal" id="aos13255-cit-0006">
<string-name>
<surname>Culham</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Chabra</surname>
<given-names>A</given-names>
</string-name> &#x00026; <string-name>
<surname>Rubin</surname>
<given-names>GS</given-names>
</string-name> (<year>2004</year>): <article-title>Clinical performance of electronic, head&#x02010;mounted, low vision devices</article-title>. <source>Ophthalmic Physiol Opt</source>
<volume>24</volume>: <fpage>281</fpage>&#x02013;<lpage>290</lpage>.<pub-id pub-id-type="pmid">15228505</pub-id></mixed-citation></ref><ref id="aos13255-bib-0007"><mixed-citation publication-type="journal" id="aos13255-cit-0007">
<string-name>
<surname>Culham</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Chabra</surname>
<given-names>A</given-names>
</string-name> &#x00026; <string-name>
<surname>Rubin</surname>
<given-names>GS</given-names>
</string-name> (<year>2009</year>): <article-title>Users&#x02019; subjective evaluation of electronic vision enhancement systems</article-title>. <source>Ophthalmic Physiol Opt</source>
<volume>29</volume>: <fpage>138</fpage>&#x02013;<lpage>149</lpage>.<pub-id pub-id-type="pmid">19236583</pub-id></mixed-citation></ref><ref id="aos13255-bib-0008"><mixed-citation publication-type="book" id="aos13255-cit-0008">
<string-name>
<surname>Curtis</surname>
<given-names>L</given-names>
</string-name> (<year>2011</year>): <source>Unit costs of health and social care 2011</source>. <publisher-loc>Canterbury</publisher-loc>: <publisher-name>Personal Social Services Research Unit, University of Kent</publisher-name>. ISSN: 1368&#x02010;230X. ISBN: 978&#x02010;1&#x02010;902671&#x02010;74&#x02010;1.</mixed-citation></ref><ref id="aos13255-bib-0009"><mixed-citation publication-type="book" id="aos13255-cit-0009">
<string-name>
<surname>Curtis</surname>
<given-names>L</given-names>
</string-name> (<year>2014</year>). <source>Unit costs of health and social care 2014</source>. <publisher-loc>Canterbury</publisher-loc>: <publisher-name>Personal Social Services Research Unit, University of Kent</publisher-name>. ISSN: 1368&#x02010;230X. ISBN: 978&#x02010;1&#x02010;902671&#x02010;89&#x02010;5.</mixed-citation></ref><ref id="aos13255-bib-0010"><mixed-citation publication-type="journal" id="aos13255-cit-0010">
<collab collab-type="authors">Euroqol Group</collab>
(<year>1990</year>): <article-title>EuroQoL &#x02013; a new facility for the measurement of health&#x02010;related quality of life</article-title>. <source>Health Policy</source>
<volume>16</volume>: <fpage>199</fpage>&#x02013;<lpage>208</lpage>.<pub-id pub-id-type="pmid">10109801</pub-id></mixed-citation></ref><ref id="aos13255-bib-0011"><mixed-citation publication-type="journal" id="aos13255-cit-0011">
<string-name>
<surname>Evans</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Fletcher</surname>
<given-names>AE</given-names>
</string-name> &#x00026; <string-name>
<surname>Wormald</surname>
<given-names>RPL</given-names>
</string-name> (<year>2007</year>): <article-title>Depression and anxiety in visually impaired older people</article-title>. <source>Ophthalmology</source>
<volume>114</volume>: <fpage>283</fpage>&#x02013;<lpage>288</lpage>.<pub-id pub-id-type="pmid">17270678</pub-id></mixed-citation></ref><ref id="aos13255-bib-0012"><mixed-citation publication-type="journal" id="aos13255-cit-0012">
<string-name>
<surname>Herdman</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gudex</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Lloyd</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Janssen</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kind</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Parkin</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Bonsel</surname>
<given-names>G</given-names>
</string-name> &#x00026; <string-name>
<surname>Badia</surname>
<given-names>X</given-names>
</string-name> (<year>2011</year>): <article-title>Development and preliminary testing of the new five&#x02010;level version of EQ&#x02010;5D (EQ&#x02010;5D&#x02010;5L)</article-title>. <source>Qual Life Res</source>
<volume>20</volume>: <fpage>1727</fpage>&#x02013;<lpage>1736</lpage>.<pub-id pub-id-type="pmid">21479777</pub-id></mixed-citation></ref><ref id="aos13255-bib-0013"><mixed-citation publication-type="journal" id="aos13255-cit-0013">
<string-name>
<surname>van Hout</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Janssen</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Feng</surname>
<given-names>YS</given-names>
</string-name> et&#x000a0;al. (<year>2012</year>): <article-title>Interim scoring for the EQ&#x02010;5D&#x02010;5L: mapping the EQ&#x02010;5D&#x02010;5L to EQ&#x02010;5D&#x02010;3L value sets</article-title>. <source>Value Health</source>
<volume>15</volume>: <fpage>708</fpage>&#x02013;<lpage>715</lpage>.<pub-id pub-id-type="pmid">22867780</pub-id></mixed-citation></ref><ref id="aos13255-bib-0014"><mixed-citation publication-type="journal" id="aos13255-cit-0014">
<string-name>
<surname>Janssen</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Pickard</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Golicki</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Gudex</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Niewada</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Scalone</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Swinburn</surname>
<given-names>P</given-names>
</string-name> &#x00026; <string-name>
<surname>Busschbach</surname>
<given-names>J</given-names>
</string-name> (<year>2013</year>): <article-title>Measurement properties of the EQ&#x02010;5D&#x02010;5L compared to the EQ&#x02010;5D&#x02010;3L across eight patient groups: a multi&#x02010;country study</article-title>. <source>Qual Life Res</source>
<volume>22</volume>: <fpage>1717</fpage>&#x02013;<lpage>1727</lpage>.<pub-id pub-id-type="pmid">23184421</pub-id></mixed-citation></ref><ref id="aos13255-bib-0015"><mixed-citation publication-type="journal" id="aos13255-cit-0015">
<string-name>
<surname>Longworth</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Young</surname>
<given-names>T</given-names>
</string-name> et&#x000a0;al. (<year>2014</year>): <article-title>Use of generic and condition&#x02010;specific measures of health&#x02010;related quality of life in NICE decision&#x02010;making: a systematic review, statistical modelling and survey</article-title>. <source>Health Technol Assess</source>
<volume>18</volume>: <fpage>1</fpage>&#x02013;<lpage>224</lpage>.</mixed-citation></ref><ref id="aos13255-bib-0016"><mixed-citation publication-type="journal" id="aos13255-cit-0016">
<string-name>
<surname>Lowe</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Spitzer</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Grafe</surname>
<given-names>K</given-names>
</string-name> et&#x000a0;al. (<year>2004</year>): <article-title>Comparative validity of three screening questionnaires for DSM&#x02010;IV depressive disorders and physicians&#x02019; diagnoses</article-title>. <source>J Affect Disord</source>
<volume>78</volume>: <fpage>131</fpage>&#x02013;<lpage>140</lpage>.<pub-id pub-id-type="pmid">14706723</pub-id></mixed-citation></ref><ref id="aos13255-bib-0017"><mixed-citation publication-type="journal" id="aos13255-cit-0017">
<string-name>
<surname>Massof</surname>
<given-names>RW</given-names>
</string-name> (<year>2007</year>): <article-title>An interval&#x02010;scaled scoring algorithm for visual function questionnaires</article-title>. <source>Optom Vis Sci</source>
<volume>84</volume>: <fpage>689</fpage>&#x02013;<lpage>705</lpage>.</mixed-citation></ref><ref id="aos13255-bib-0018"><mixed-citation publication-type="journal" id="aos13255-cit-0018">
<string-name>
<surname>McIlwaine</surname>
<given-names>GG</given-names>
</string-name>, <string-name>
<surname>Bell</surname>
<given-names>JA</given-names>
</string-name> &#x00026; <string-name>
<surname>Dutton</surname>
<given-names>GN</given-names>
</string-name> (<year>1991</year>): <article-title>Low vision aids &#x02013; is our service cost effective?</article-title>
<source>Eye</source>
<volume>5</volume>: <fpage>607</fpage>&#x02013;<lpage>611</lpage>.<pub-id pub-id-type="pmid">1794428</pub-id></mixed-citation></ref><ref id="aos13255-bib-0019"><mixed-citation publication-type="journal" id="aos13255-cit-0019">
<string-name>
<surname>Misajon</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Hawthorne</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Richardson</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Barton</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Peacock</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Iezzi</surname>
<given-names>A</given-names>
</string-name> &#x00026; <string-name>
<surname>Keeffe</surname>
<given-names>J</given-names>
</string-name> (<year>2005</year>): <article-title>Vision and quality of life: the development of a utility measure</article-title>. <source>Invest Ophthalmol Vis Sci</source>
<volume>46</volume>: <fpage>4007</fpage>&#x02013;<lpage>4015</lpage>.<pub-id pub-id-type="pmid">16249474</pub-id></mixed-citation></ref><ref id="aos13255-bib-0020"><mixed-citation publication-type="journal" id="aos13255-cit-0020">
<string-name>
<surname>Mitchell</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Roberts</surname>
<given-names>TE</given-names>
</string-name>, <string-name>
<surname>Barton</surname>
<given-names>PM</given-names>
</string-name> &#x00026; <string-name>
<surname>Coast</surname>
<given-names>J</given-names>
</string-name> (<year>2015</year>): <article-title>Assessing sufficient capability; a new approach to economic evaluation</article-title>. <source>Soc Sci Med</source>
<volume>139</volume>: <fpage>71</fpage>&#x02013;<lpage>79</lpage>.<pub-id pub-id-type="pmid">26164118</pub-id></mixed-citation></ref><ref id="aos13255-bib-0021"><mixed-citation publication-type="book" id="aos13255-cit-0021">
<string-name>
<surname>Mogyorosy</surname>
<given-names>Z</given-names>
</string-name> &#x00026; <string-name>
<surname>Smith</surname>
<given-names>P</given-names>
</string-name> (<year>2005</year>). <source>The main methodological issues in costing health care services: a literature review</source>. <publisher-loc>York</publisher-loc>: <publisher-name>Centre for Health Economics, University of York</publisher-name>.</mixed-citation></ref><ref id="aos13255-bib-0022"><mixed-citation publication-type="book" id="aos13255-cit-0022">
<collab collab-type="authors">National Institute for Health and Care Excellence [NICE]</collab>
(<year>2013</year>). <source>Guide to the methods of technology appraisal</source>. <publisher-loc>London</publisher-loc>: <publisher-name>National Institute for Health and Care Excellence</publisher-name>.</mixed-citation></ref><ref id="aos13255-bib-0023"><mixed-citation publication-type="journal" id="aos13255-cit-0023">
<string-name>
<surname>Nollett</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Bray</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Bunce</surname>
<given-names>C</given-names>
</string-name> et&#x000a0;al. (<year>2016</year>): <article-title>High prevalence of untreated depression in patients accessing low&#x02010;vision services</article-title>. <source>Ophthalmology</source>
<volume>123</volume>: <fpage>440</fpage>&#x02013;<lpage>441</lpage>.<pub-id pub-id-type="pmid">26278862</pub-id></mixed-citation></ref><ref id="aos13255-bib-0024"><mixed-citation publication-type="journal" id="aos13255-cit-0024">
<string-name>
<surname>Peacock</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Misajon</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Iezzi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Richardson</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hawthorne</surname>
<given-names>G</given-names>
</string-name> &#x00026; <string-name>
<surname>Keeffe</surname>
<given-names>J</given-names>
</string-name> (<year>2008</year>): <article-title>Vision and quality of life: development of methods for the VisQoL vision&#x02010;related utility instrument</article-title>. <source>Ophthalmic Epidemiol</source>
<volume>15</volume>: <fpage>218</fpage>&#x02013;<lpage>223</lpage>.<pub-id pub-id-type="pmid">18780254</pub-id></mixed-citation></ref><ref id="aos13255-bib-0025"><mixed-citation publication-type="journal" id="aos13255-cit-0025">
<string-name>
<surname>Peterson</surname>
<given-names>RC</given-names>
</string-name>, <string-name>
<surname>Wolffsohn</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Rubinstein</surname>
<given-names>M</given-names>
</string-name> &#x00026; <string-name>
<surname>Lowe</surname>
<given-names>J</given-names>
</string-name> (<year>2003</year>): <article-title>Benefits of electronic vision enhancement systems (EVES) for the visually impaired</article-title>. <source>Am J Ophthalmol</source>
<volume>136</volume>: <fpage>1129</fpage>&#x02013;<lpage>1135</lpage>.<pub-id pub-id-type="pmid">14644225</pub-id></mixed-citation></ref><ref id="aos13255-bib-0026"><mixed-citation publication-type="book" id="aos13255-cit-0026">
<collab collab-type="authors">Royal College of Nursing</collab>
(<year>2014</year>): <article-title>Pay rates 2014&#x02010;15</article-title>. <publisher-loc>London</publisher-loc>: <publisher-name>Royal College of Nursing</publisher-name> Available at: <ext-link ext-link-type="uri" xlink:href="https://www.rcn.org.uk/support/pay_and_conditions/pay_rates_2014-15">https://www.rcn.org.uk/support/pay_and_conditions/pay_rates_2014-15</ext-link>. (Accessed on 3 Mar 2016).</mixed-citation></ref><ref id="aos13255-bib-0027"><mixed-citation publication-type="journal" id="aos13255-cit-0027">
<string-name>
<surname>Stelmack</surname>
<given-names>JA</given-names>
</string-name> &#x00026; <string-name>
<surname>Massof</surname>
<given-names>RW</given-names>
</string-name> (<year>2007</year>): <article-title>Using the VA LV VFQ&#x02010;48 and LV VFQ&#x02010;20 in low vision rehabilitation</article-title>. <source>Optom Vis Sci</source>
<volume>84</volume>: <fpage>705</fpage>&#x02013;<lpage>709</lpage>.<pub-id pub-id-type="pmid">17700334</pub-id></mixed-citation></ref><ref id="aos13255-bib-0028"><mixed-citation publication-type="journal" id="aos13255-cit-0028">
<string-name>
<surname>Taylor</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bambrick</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Dutton</surname>
<given-names>M</given-names>
</string-name> et&#x000a0;al. (<year>2014</year>): <article-title>The p&#x02010;EVES study design and methodology: a randomised controlled trial to compare portable electronic vision enhancement systems (p&#x02010;EVES) to optical magnifiers for near vision activities in visual impairment</article-title>. <source>Ophthalmic Physiol Opt</source>
<volume>34</volume>: <fpage>558</fpage>&#x02013;<lpage>572</lpage>.<pub-id pub-id-type="pmid">25115201</pub-id></mixed-citation></ref><ref id="aos13255-bib-0029"><mixed-citation publication-type="journal" id="aos13255-cit-0029">
<string-name>
<surname>Tosh</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Brazier</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Evans</surname>
<given-names>P</given-names>
</string-name> &#x00026; <string-name>
<surname>Longworth</surname>
<given-names>L</given-names>
</string-name> (<year>2012</year>): <article-title>A review of generic preference&#x02010;based measures of health&#x02010;related quality of life in visual disorders</article-title>. <source>Value Health</source>
<volume>15</volume>: <fpage>118</fpage>&#x02013;<lpage>127</lpage>.<pub-id pub-id-type="pmid">22264979</pub-id></mixed-citation></ref></ref-list></back></article>